Navigation Links
Biolex presents Locteron US Phase 2a hepatitis C data at EASL
Date:4/24/2009

developed by OctoPlus N.V. of Leiden, the Netherlands. Locteron is configured to allow dosing once every two weeks, more convenient than Pegasys and PEG-Intron, each of which require dosing every week. More importantly, Locteron's controlled-release mechanism results in the gradual release of interferon alpha 2b to patients over the duration of two weeks and avoids the early peak plasma levels of the active interferon that characterize the pegylated interferons and Albuferon. This controlled-release mechanism is designed to reduce the frequency, duration and severity of side effects, including flu-like symptoms, commonly experienced by patients treated with pegylated interferons and with Albuferon. The Company has completed three clinical trials of Locteron, and a Phase 2b trial is currently ongoing in 100 chronic genotype-1 hepatitis C patients in the United States and Europe.


'/>"/>

Contact: Michelle Linn
linnmich@comcast.net
508-362-3087
Linnden Communications
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. GSA special paper presents new studies of Western US earth motion
2. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
3. AIUM presents 2009 Memorial Hall of Fame awards
4. AIUM presents 2009 Distinguished Sonographer award
5. AIUM presents 2009 William J. Fry Memorial Lecture award
6. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
7. Understanding soil carbon sequestration: New book presents key concepts
8. World Congress on Osteoporosis 2010 presents outstanding scientific program
9. New manual presents robust, state-of-the-art proteomics methods for teaching and research
10. Arbor Vita presents new data on cancer diagnostic at EUrogin
11. Soil Science Society of America presents awards in Houston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... a multitude of cells types. Researchers would like to understand ... mature cells that make up the organs and other structures ... long chains of sugars that dangle from proteins on surfaces ... California, San Diego, has created synthetic molecules that can stand ... manipulated to direct the process, they report in the ...
(Date:7/29/2014)... by academics in the University of Bristol,s Nutrition and ... liquid calories into account when planning meals. , The ... Study of Ingestive Behavior Conference (SSIB 2014) in Seattle, ... that we do. , The team was led by ... of Experimental Psychology. , As part of a Biotechnology ...
(Date:7/29/2014)... 2014 Research and Markets  has announced ... (BI) Market 2014-2018" report to their offering. ... The term BI refers to applications and technologies that ... information about a company,s operations. BI help organizations to ... for example, metrics on sales, production, and internal operations. ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2
... increase in the number of infections with a specific ... Salmonella serovar Typhimurium DT104, is resistant to at least ... genetic information in DNA of DT104 that might be ... information might also be involved in the increase in ...
... clinical trials, coronary artery bypass surgery performed on a beating ... safe option that leads to fewer negative side effects for ... Surgery. , “Previously, it was more common for doctors ... the heart and passing the blood through a heart-lung machine,?says ...
... key enzyme can soothe over-excited receptors in the brain, ... Alzheimer's and other neurodegenerative diseases. , Lead author Michel ... student Wei Xu and collaborators from the University of ... issue of Neuron. , The researchers injected ...
Cached Biology News:Salmonella survives better in stomach due to altered DNA 2Decoy pill saves brain cells 2
(Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 Adding ... their weighing boat special – Buy 2 ... free. This promotion will benefit lab technicians looking for ... Weighing boats are ideal for multiple applications including weighing ... a variety of choices including diamond-shaped, hexagonal, square, aluminum ...
(Date:7/29/2014)... 2014 “PharmaSphere: Emerging Biotech Investment ... Capital Funding” report provides in-depth analysis of the ... and venture capital segments of the financial industry, ... have significant impact on the future of emerging ... the report identifies regions of the world that ...
Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4
... science and public policy with the needs of consumers ... any chance of reducing the effects of carbon on ... of the American Association for the Advancement of Science ... the global energy system, says Mike Davis, who leads ...
... morally acceptable? , For a significant percentage of Americans, ... of Americans, attitudes about the science of the very ... at the annual meeting of the American Association for ... Wisconsin-Madison professor of life sciences communication, presented new survey ...
... Therapies that Significantly Raises HDL "Good" Cholesterol and ... ... ABBOTT PARK, Ill., Feb. 15 Today, Abbott,received U.S. Food ... two widely prescribed cholesterol,therapies, Niaspan(R) (Abbott,s proprietary niacin extended-release) and,simvastatin. SIMCOR ...
Cached Biology Technology:Mission critical for carbon management 2Mission critical for carbon management 3Religion colors Americans' views of nanotechnology 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 3Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 4Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 5Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 6
Fetal Calf Serum Replacement (Bistec) serum...
NEWBORN CALF SERUM AND PLASMA...
... Solid phase reagent ... purification; Easy & unique ... Compatible with detergents and ... & recover non-envelop viruses ...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
Biology Products: